Information Provided By:
Fly News Breaks for June 26, 2017
CELG
Jun 26, 2017 | 08:34 EDT
Data suggests that Celgene's new treatment for refractory follicular non-Hodgkin lymphoma, CelMod CC-122, "appears more active" than its current treatment, Revlimid, according to Wells Fargo. The firm thinks the data suggests that the company's strategy for fending off generic competition, due in 2023, could work. It keeps an Outperform rating on Celgene.
News For CELG From the Last 2 Days
There are no results for your query CELG